

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

David Brown, et al.

Examiner:

Unassigned

Serial No.:

10/519,534

Group Art Unit:

Unassigned

Confirmation No:

Unassigned

Docket:

178-312 PCT/US

Filed:

December 27, 2004

Dated:

March 7, 2005

For:

METHOD FOR REDUCING C-REACTIVE PROTEIN LEVELS WITH NON-ANTIBACTERIAL TETRACYCLINE FORMULATIONS

Commissioner for Patents PO Box 1450

PO Box 1450 Alexandria, Virginia 22313-01450 I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to:

Commissioner for Patents, PO Box 1450, Alexandria,

ILDID.

Virginia, 22313-1450 on March 7, 2005

Dated: 3/7/05

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

NON-PATENT PUBLICATIONS

- 1. Brown, David L., et al., "Clinical and Biochemical Results of the Metalloproteinase Inhibition with Subantimicrobial Doses of Doxycycline to Prevent Acute Coronary Syndromes (MIDAS) Pilot Trial", *Arteriosclerosis, Thrombosis and Vascular Biology* 2004, 24(4):733-738.
- 2. Brown, D.L., et al., "Effect of Sub-antimicrobial Doxycycline on Biomarkers in Patients with Acute Coronary Syndromes", *J. Dent. Res.* 2003, 82 (Special Issue): 1443.

Application No.: 10/51
Filing Date: December 27,2004
Docket No.: 178-312 PCT/US

Page 2 of 2

3. Golub, L.M., et al., "Sub-Antimicrobial Doxycycline (SDD) Reduces Biomarkers of Inflammation in Acute Coronary Syndromes (ACS) and Periodontitis Patients", *Inflammation Research* July 2003, 52(Supplement 2):S157.

The above-referenced documents are listed on PTO Form 1449. We have enclosed the cited document to facilitate reference to it.

Applicants are not aware of any other references to be identified at this time. If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' attorney at the telephone number set forth below.

Respectfully submitted,

Lauren T. Emr

Registration No.: 46,139 Attorney for Applicant(s)

HOFFMANN & BARON, LLP 6900 Jericho Turnpike Syosset, New York 11791 (516) 822-3550 LTE:jlw

THE PARTY OF THE P				Sheet 1 of	
FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 178-312 PCT/US	SERIAL NO. 10/519,534	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT Brown et al.	CONFIRMATION NO. Unassigned	
(Use several sheets if necessary)			FILING DATE December 27, 2004	GROUP Unassigned	
	OTHER	DOCUMENTS (Including Author	, Title, Date, Pertinent P	ages, Etc.)	
		Brown, David L., et al., "Clini Metalloproteinase Inhibition w Prevent Acute Coronary Synd	Brown, David L., et al., "Clinical and Biochemical Results of the Metalloproteinase Inhibition with Subantimicrobial Doses of Doxycycline to Prevent Acute Coronary Syndromes (MIDAS) Pilot Trial", Arteriosclerosis, Thrombosis and Vascular Biology 2004, 24(4):733-738.		
		Brown, D.L., et al., "Effect of in Patients with Acute Corona	Sub-antimicrobial Doxy	cycline on Biomarkers	

Issue): 1443.

2):S157.

201599_1

EXAMINER

DATE CONSIDERED

Golub, L.M., et al., "Sub-Antimicrobial Doxycycline (SDD) Reduces Biomarkers of Inflammation in Acute Coronary Syndromes (ACS) and Periodontitis Patients", Inflammation Research July 2003, 52(Supplement

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.